The ability of hydrazino-isatin-based benzenesulfonamides in the inhibition of cyclin-dependent kinase 2 (CDK2) were previously reported, exhibiting antiproliferative activity against different cancer cell lines HT29, MDAMB468, RKO and SW620. This evidence concerns the gene CDK2 and cancer.